Not yet recruitingInterventionalPhase 2Last updated Aug 14, 2026

Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC

A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)

Overview

ClinicalTrials.gov ID: NCT07765836
Lead Sponsor: Massachusetts General HospitalOTHER
Brief Summary: This is a single arm, open-label, non-randomized multi-institution phase II trial of a Fc enhanced CTLA4 antibody, vilastobart, in combination with PD-1 antibody, retifanlimab, in patients with BRCA1, BRCA2 or PALB2 deficient pancreatic cancer (PC).
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Jan 2027Estimated
Primary Completion Date: Dec 31, 2028Estimated
Completion Date: Dec 31, 2030Estimated

Study Record Dates

First Submitted: Aug 10, 2026
First Submitted that Met QC Criteria: Aug 10, 2026
First Posted: Aug 14, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 10, 2026
Last Update Posted: Aug 14, 2026Actual
Last Verified: Aug 2026

NCT00925769Completed

ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer

NCT02907099Completed

Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

NCT04976634Active, not recruiting

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

NCT05558982Active, not recruiting

BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT05669482Active, not recruiting

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

NCT05093231Recruiting

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer